News
LGND
72.52
-8.05%
-6.35
Jazz Pharmaceuticals: Cheap But Complicated
Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz. Jazz's oncology franchise is expected to contribute around $1.5 billion in revenue. The shares are now trading at less than six times forward earnings.
Seeking Alpha · 19h ago
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
NASDAQ · 23h ago
Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know
NASDAQ · 1d ago
Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why
NASDAQ · 2d ago
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
NASDAQ · 2d ago
Corcept (CORT) Completes Enrollment in Phase II ALS Study
NASDAQ · 2d ago
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
NASDAQ · 2d ago
J&J sets guidance below consensus as MedTech underperforms
Johnson & Johnson sets guidance below consensus as MedTech underperforms in Q1 2024. The pharma giant's sales from its MedTech division fell short of Street forecasts. J&J shares slipped in the premarket after the results. The company revised its full-year 2024 revenue outlook below consensus.
Seeking Alpha · 3d ago
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
NASDAQ · 3d ago
Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors
NASDAQ · 3d ago
Weekly Report: what happened at LGND last week (0408-0412)?
Weekly Report · 4d ago
AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids
NASDAQ · 6d ago
Ligand Pharmaceuticals Price Target Maintained With a $95.00/Share by Benchmark
Dow Jones · 6d ago
Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
Benzinga · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Select Medical (SEM), Ligand Pharma (LGND)
TipRanks · 04/12 11:23
Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
NASDAQ · 04/09 17:34
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
NASDAQ · 04/09 15:09
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
NASDAQ · 04/09 15:07
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
NASDAQ · 04/08 17:51
Ligand Pharmaceuticals Announces Topiramate Injection Data At 9th London-Innsbruck Colloquium On Status Epilepticus And Acute Seizures Conference
Benzinga · 04/08 12:27
More
Webull provides a variety of real-time LGND stock news. You can receive the latest news about Ligand Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.